東華大學圖書館 |

Synthesis of Small Molecules that Break Colistin Resistance /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Synthesis of Small Molecules that Break Colistin Resistance // Haoting Li.
作者:	Li, Haoting,
面頁冊數:	1 electronic resource (338 pages)
附註:	Source: Dissertations Abstracts International, Volume: 85-07, Section: B.
Contained By:	Dissertations Abstracts International85-07B.
標題:	Chemistry. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30813797
ISBN:	9798381381726

Synthesis of Small Molecules that Break Colistin Resistance /
Li, Haoting,

Synthesis of Small Molecules that Break Colistin Resistance /Haoting Li. - 1 electronic resource (338 pages)

Source: Dissertations Abstracts International, Volume: 85-07, Section: B.

Addressing the escalating threat of antibiotic-resistant bacteria is imperative for the survival of modern healthcare systems. Among all bacterial pathogens, the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) are responsible for many of the most difficult to treat infections as a result of high levels of multidrug resistance. Given the lack of investment from big pharmaceutical companies in discovering new classes of antibiotics against Gram-negative bacteria in recent decades, physicians have turned to the use of polymyxins, which are typically viewed as the antibiotics of last resort for the treatment of multidrug-resistant (MDR) Gram-negative infections. However, the nephrotoxic side effects that once caused the suspension of colistin should not be ignored. In parallel with the development of new conventional antibiotics is the use of non-microbicidal small molecule adjuvants that disrupt bacterial resistance mechanisms. In the context of colistin resistance, we and others have identified a number of adjuvants that suppress resistance in bacterial strains that harbor either chromosomally or plasmid encoded resistance determinants. A series of screening efforts using eukaryotic kinase and phosphatase inhibitors yielded several compounds as highly active colistin adjuvants. The following research describes the synthesis of derivatives of three scaffolds identified from these screens, and evaluation of their biological activity. For benzimidazole derivatives, structure-activity relationship (SAR) studies were conducted, leading to the identification of four derivatives with distinct activities, which were further investigated to understand their mechanism of action and potential pharmaceutical concerns. Unexpectedly, MALDI mass spectrometry detected no changes in the lipid A composition of strains with a colistin resistant phenotype, while quantitative RT-PCR (qRT-PCR) disclosed insignificant changes in the expression of genes involved in resistance pathways. Therefore, the mechanism of action of how these compounds potentiate colistin still remains unclear. By measuring interaction of the active compounds with IKKs via a luciferase assay, we proved it is possible to decouple colistin adjuvant activity from eukaryotic kinase activity for the benzimidazole scaffold. Similar research was also conducted with 6-bromoindirubin-3'-oxime derivatives. We have synthesized and tested a library of indirubin analogs for restoration of colistin susceptibility in colistin resistant bacteria. The most active compound lowered the colistin MIC in KPB9 below the breakpoint. No hemolysis was noted for the most active compound up to 400 μM (80x its active concentration against all strains tested), while mechanism of action studies indicate that colistin potentiation is not dependent upon full reversal of lipid A modification. We also recently discovered the indolic marine natural product meridianin D, which is also a kinase inhibitor, as a highly active colistin potentiator against representative colistin resistant K. pneumoniae and A. baumannii strains. This discovery inspired us to find potential antibiotic potentiators from other natural products. The National Cancer institute (NCI) Developmental Therapeutics Program is a library that includes more than 230,000 natural products purified from various plant, marine, and microbial samples. From a subset of this library, another natural product variabiline (4.1) was found to be active against colistin susceptible K. pneumoniae 2146 and A. baumannii 5075 strains. We performed the total synthesis and SAR study of this natural product. Chiral resolution followed by X-ray analysis was also conducted to resolve a 1H NMR discrepancy between our data and published data. Both enantiomers of variabiline were determined to have same level of activity. This observation reinforces our expectation that variabiline increases colistin activity by increasing membrane permeability. Mechanism of action studies suggest that variabiline increases the permeability of Gram-negative outer membrane (OM), but not through direct interaction with lipopolysaccharide (LPS).

English

ISBN: 9798381381726Subjects--Topical Terms:

516420
Chemistry.

Synthesis of Small Molecules that Break Colistin Resistance /
LDR:05540nmm a22003853i 4500 001 2400512
005 20250522084143.5
006 m o d
007 cr|nu||||||||
008 251215s2024 miu||||||m |||||||eng d
020 $a 9798381381726
035 $a (MiAaPQD)AAI30813797
035 $a AAI30813797
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Li, Haoting, $e author. $3 3770535
245 1 0 $a Synthesis of Small Molecules that Break Colistin Resistance / $c Haoting Li.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2024
300 $a 1 electronic resource (338 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 85-07, Section: B.
500 $a Advisors: Melander, Christian Committee members: Taylor, Richard; Del Valle, Juan.
502 $b Ph.D. $c University of Notre Dame $d 2024.
520 $a Addressing the escalating threat of antibiotic-resistant bacteria is imperative for the survival of modern healthcare systems. Among all bacterial pathogens, the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) are responsible for many of the most difficult to treat infections as a result of high levels of multidrug resistance. Given the lack of investment from big pharmaceutical companies in discovering new classes of antibiotics against Gram-negative bacteria in recent decades, physicians have turned to the use of polymyxins, which are typically viewed as the antibiotics of last resort for the treatment of multidrug-resistant (MDR) Gram-negative infections. However, the nephrotoxic side effects that once caused the suspension of colistin should not be ignored. In parallel with the development of new conventional antibiotics is the use of non-microbicidal small molecule adjuvants that disrupt bacterial resistance mechanisms. In the context of colistin resistance, we and others have identified a number of adjuvants that suppress resistance in bacterial strains that harbor either chromosomally or plasmid encoded resistance determinants. A series of screening efforts using eukaryotic kinase and phosphatase inhibitors yielded several compounds as highly active colistin adjuvants. The following research describes the synthesis of derivatives of three scaffolds identified from these screens, and evaluation of their biological activity. For benzimidazole derivatives, structure-activity relationship (SAR) studies were conducted, leading to the identification of four derivatives with distinct activities, which were further investigated to understand their mechanism of action and potential pharmaceutical concerns. Unexpectedly, MALDI mass spectrometry detected no changes in the lipid A composition of strains with a colistin resistant phenotype, while quantitative RT-PCR (qRT-PCR) disclosed insignificant changes in the expression of genes involved in resistance pathways. Therefore, the mechanism of action of how these compounds potentiate colistin still remains unclear. By measuring interaction of the active compounds with IKKs via a luciferase assay, we proved it is possible to decouple colistin adjuvant activity from eukaryotic kinase activity for the benzimidazole scaffold. Similar research was also conducted with 6-bromoindirubin-3'-oxime derivatives. We have synthesized and tested a library of indirubin analogs for restoration of colistin susceptibility in colistin resistant bacteria. The most active compound lowered the colistin MIC in KPB9 below the breakpoint. No hemolysis was noted for the most active compound up to 400 μM (80x its active concentration against all strains tested), while mechanism of action studies indicate that colistin potentiation is not dependent upon full reversal of lipid A modification. We also recently discovered the indolic marine natural product meridianin D, which is also a kinase inhibitor, as a highly active colistin potentiator against representative colistin resistant K. pneumoniae and A. baumannii strains. This discovery inspired us to find potential antibiotic potentiators from other natural products. The National Cancer institute (NCI) Developmental Therapeutics Program is a library that includes more than 230,000 natural products purified from various plant, marine, and microbial samples. From a subset of this library, another natural product variabiline (4.1) was found to be active against colistin susceptible K. pneumoniae 2146 and A. baumannii 5075 strains. We performed the total synthesis and SAR study of this natural product. Chiral resolution followed by X-ray analysis was also conducted to resolve a 1H NMR discrepancy between our data and published data. Both enantiomers of variabiline were determined to have same level of activity. This observation reinforces our expectation that variabiline increases colistin activity by increasing membrane permeability. Mechanism of action studies suggest that variabiline increases the permeability of Gram-negative outer membrane (OM), but not through direct interaction with lipopolysaccharide (LPS).
546 $a English
590 $a School code: 0165
650 4 $a Chemistry. $3 516420
650 4 $a Microbiology. $3 536250
650 4 $a Pharmacology. $3 634543
650 4 $a Molecular chemistry. $3 1071612
690 $a 0485
690 $a 0431
690 $a 0410
690 $a 0419
710 2 $a University of Notre Dame. $b Chemistry and Biochemistry. $e degree granting institution. $3 3770479
720 1 $a Melander, Christian $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 85-07B.
790 $a 0165
791 $a Ph.D.
792 $a 2024
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30813797